COVID-19 patients who had pneumonia symptoms developed IgA earlier than the mild cases (11.5 days (IQR = 0.5–20.5) for patients with pneumonia versus 22 days (IQR = 14–26) for mild cases) (Table 1 and S1 Table). Here, CD79A is linked to susceptibility to pneumonia measurement.